OncLive TV

Ruchi J. Desai, MD, discusses future research directions in MPN and other hematologic malignancies.

Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.

Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.

Matthew R. Smith, MD, PhD, discusses how radioligand therapies are altering the prostate cancer treatment paradigm.

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

Harry Erba, MD, PhD, discusses the significance of the FDA approval of ziftomenib in NMP1-mutant, relapsed/refractory acute myeloid leukemia.

Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

Ruchi J. Desai, MD, discusses the current standing of JAK inhibitors in the treatment landscape of myeloproliferative neoplasms.

Matthew R. Smith, MD, PhD, discusses what the future of prostate cancer research may look like.

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Joaquim Bellmunt, MD, PhD, discusses subgroup and safety data from the phase 3 IMvigor011 trial in patients with MIBC.

Antonio Gonzalez-Martin, MD, discusses the design of the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.

Ticiana Leal, MD, discusses clinical considerations surrounding the diagnosis of LEMS in patients with lung cancer.

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

Ruchi J. Desai, MD, discusses several notable ongoing studies examining agents for the treatment of patients with myeloproliferative neoplasms.

Marc S. Raab, MD, outlines the safety profile of teclistamab plus Dara-VRd in newly diagnosed multiple myeloma from the MajesTEC-5 trial.

Cassie Kline, MD, MAS, discusses 3-year follow-up data with tovorafenib in patients with pediatric low-grade glioma from FIREFLY-1.

Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.

Lauren Shaff, MD, contextualizes results from a phase 1 study evaluating copanlisib plus ibrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Stephen Freedland, MD, discusses how the efficacy findings of each arm of the phase 3 EMBARK trial in prostate cancer stacked up with one another.

Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.

Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.

Giuseppe Lombardi, MD, PhD, discusses data with regorafenib plus temozolomide and radiation in newly diagnosed, MGMT-methylated, IDH-wild-type glioblastoma.

Angela C. Hirbe, MD, PhD, discusses long-term follow-up data from the phase 2b ReNeu trial evaluating mirdametinib in patients with NF1-associated symptomatic PN.

Matthew R. Smith, MD, PhD, discusses the role of darolutamide in mHSPC following its approval as monotherapy.